M. Rodrigues Bacci, Emery Ciana Figueiredo Vidal, Glaucia Luciano da Veiga, Eglidia Carla Figueiredo Vidal, Beatriz da C. Aguiar Alves, T. Gascón, F. L. Affonso Fonseca
{"title":"Yellow fever vaccination in hemodialysis patients: A systematic review","authors":"M. Rodrigues Bacci, Emery Ciana Figueiredo Vidal, Glaucia Luciano da Veiga, Eglidia Carla Figueiredo Vidal, Beatriz da C. Aguiar Alves, T. Gascón, F. L. Affonso Fonseca","doi":"10.2174/1574885518666230123160533","DOIUrl":null,"url":null,"abstract":"\n\nYellow fever is an infectious disease endemic to Africa, and Central and\nSouth America with a significant impact on public health, causing outbreaks and epidemics. Clinical\nmanifestations can vary from asymptomatic to more severe and lethal disease outcomes. The primary\nprevention of yellow fever occurs through the vaccination of individuals, which confers immunity for\nlife. Patients with chronic kidney disease, especially those undergoing dialysis, have low vaccination\nand seroconversion rates. As mentioned above, this research aimed to perform a systematic review of\nthe yellow fever vaccination protocol in hemodialysis patients\n\n\n\nA systematic review on vaccination against yellow fever in hemodialysis patients using databases, PubMed and Biblioteca Virtual em Saúde (BVS), was performed. For data collection, combinations were made using the following descriptors: protocols, vaccination, yellow fever, kidney dialysis, chronic kidney failure, chronic kidney disease, and group risk included in the title and abstract description. Articles with no subject related to the search were excluded and also if they were duplicated.\n\n\n\nIn this review, 90 scientific articles were identified in both databases. After applying exclusion criteria, a total of 3 articles were selected.\n\n\n\nWe recommend carefully assessing the risk-benefit and contraindications for the patient,\nemphasizing the risk groups. There is an evident lack of studies on the subject, and there is a need to\nbroaden investigations related toimmunization for patients on dialysis. The review is registered in the\nPROSPERO system with the number 323550.\n","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":" ","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2023-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574885518666230123160533","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Yellow fever is an infectious disease endemic to Africa, and Central and
South America with a significant impact on public health, causing outbreaks and epidemics. Clinical
manifestations can vary from asymptomatic to more severe and lethal disease outcomes. The primary
prevention of yellow fever occurs through the vaccination of individuals, which confers immunity for
life. Patients with chronic kidney disease, especially those undergoing dialysis, have low vaccination
and seroconversion rates. As mentioned above, this research aimed to perform a systematic review of
the yellow fever vaccination protocol in hemodialysis patients
A systematic review on vaccination against yellow fever in hemodialysis patients using databases, PubMed and Biblioteca Virtual em Saúde (BVS), was performed. For data collection, combinations were made using the following descriptors: protocols, vaccination, yellow fever, kidney dialysis, chronic kidney failure, chronic kidney disease, and group risk included in the title and abstract description. Articles with no subject related to the search were excluded and also if they were duplicated.
In this review, 90 scientific articles were identified in both databases. After applying exclusion criteria, a total of 3 articles were selected.
We recommend carefully assessing the risk-benefit and contraindications for the patient,
emphasizing the risk groups. There is an evident lack of studies on the subject, and there is a need to
broaden investigations related toimmunization for patients on dialysis. The review is registered in the
PROSPERO system with the number 323550.
黄热病是一种流行于非洲、中美洲和南美洲的传染病,对公共卫生产生重大影响,引起疫情和流行。临床表现可以从无症状到更严重和致命的疾病结局。黄热病的初级预防是通过个人接种疫苗实现的,这种疫苗可提供终身免疫。慢性肾脏疾病患者,尤其是透析患者,疫苗接种率和血清转换率较低。如上所述,本研究旨在对血液透析患者的黄热病疫苗接种方案进行系统评价。利用PubMed和Biblioteca Virtual em Saúde (BVS)数据库对血液透析患者的黄热病疫苗接种进行系统评价。为了收集数据,使用以下描述符进行组合:方案、疫苗接种、黄热病、肾透析、慢性肾衰竭、慢性肾脏疾病和标题和摘要描述中包含的群体风险。与检索主题无关的文章被排除在外,如果它们被重复,也被排除在外。在本综述中,在两个数据库中确定了90篇科学论文。应用排除标准后,共筛选出3篇文章。我们建议仔细评估患者的风险-收益和禁忌症,强调风险群体。这方面的研究明显缺乏,有必要扩大透析患者免疫相关的研究。该审查已在prospero系统中注册,编号为323550。
期刊介绍:
Current Drug Therapy publishes frontier reviews of high quality on all the latest advances in drug therapy covering: new and existing drugs, therapies and medical devices. The journal is essential reading for all researchers and clinicians involved in drug therapy.